This outcome did not significantly differ between the groups with SF3B1 mutation: for CMML-SF3B1 14% (1%-43%) and for MDS-SF3B1 9% (2%-24%) (p=0.929) (Figures 4A, B). This evidence concerns the gene SF3B1 and myelodysplastic syndrome.